Nicotinamide as a therapeutic agent for bone diseases
10.11620/IJOB.2024.49.3.53
- Author:
Heein YOON
1
;
Woo-Jin KIM
;
Young-Dan CHO
;
Hyun-Mo RYOO
Author Information
1. Department of Molecular Genetics and Dental Pharmacology, Dental Multiomics Center, Dental Research Institute, School of Dentistry, Seoul National University, Seoul 08826, Republic of Korea
- Publication Type:Invited Review
- From:International Journal of Oral Biology
2024;49(3):53-60
- CountryRepublic of Korea
- Language:English
-
Abstract:
Nicotinamide (NAM), a water-soluble derivative of vitamin B3, has emerged as a potential therapeutic agent for bonerelated disorders. In particular, it promotes bone metabolism and alleviates delayed tooth eruptions associated with cleidocranial dysplasia (CCD). NAM serves as a precursor for nicotinamide adenine dinucleotide, a key coenzyme involved in cellular metabolism that plays an essential role in oxidative phosphorylation and mitochondrial function.Recent research has highlighted the capacity of NAM to enhance osteogenic differentiation and regulate the interaction between osteoblasts and osteoclasts, which is critical for maintaining bone homeostasis. Moreover, the effect of NAM in preventing delayed tooth eruptions in CCD models underscores its potential as a noninvasive therapeutic option. Considering its safety profile and therapeutic potential, NAM is a promising candidate for longterm treatment of bone diseases and prevention of age-related bone disorders.
